Safety and efficiency of LASIK with combined short UV-riboflavin cross-linking compared to LASIK in patients with high myopia and myopic astigmatism

Session Details

Session Title: Moderated Poster Session: Refractive
Session Date/Time: Saturday 16/02/2019 | 14:00-15:00
Paper Time: 14:40
Venue: Poster Area


First Author: T.Kohnen GERMANY
Co Author(s): C. Lwowski  M. Herzog  K. Petermann  E. Hemkeppler  S. Schönbrunn     

Abstract Details

Purpose:

To evaluate the safety and efficiency of LASIK in patients with high myopia and myopic astigmatism combined with accelerated UV-Riboflavin crosslinking compared to conventional LASIK regarding regression of the refractive outcome.

Setting:

Prospective, randomized, intra-patient controlled, clinical study

Methods:

Twenty-six patients with myopia ranging from -6.0D to -12.0D manifest refraction spherical equivalent (MRSE) and myopic astigmatism up to -5.0D had bilateral fs-LASIK. Randomized one eye was treated with accelerated UV-Riboflavin crosslinking under the flap (XtraLASIK), the other was treated with fs-LASIK only. We compared MRSE, keratometry, uncorrected and best corrected visual acuity (UDVA, BSCVA).

Results:

One week, one, three, six, and twelve months after surgery UDVA was for the fs-LASIK eyes: -0.03±0.10logMAR, -0.05 ±0.08logMAR, -0.07±0.10logMAR, -0.07±0.08logMAR and 0.00±0.15logMAR and 0.01±0.11logMAR, -0.05±0.09logMAR, -0.09±0.08logMAR, -0.08±0.10logMAR and -0.05 ±0,11logMAR for the XtraLASIK eyes. MRSE was stable during the complete follow up with (-0.02±0.42, -0.06±0.33, -0.15±0.2, -0.09±0.31, and -0.25±0.46D) in the fs-LASIK and (-0,08±0.26,-0.1±0.3,-0.1±0.3, -0.17±0.29,-0.17±0.42D) in the XtraLASIK group. There was no case of post LASIK ectasia observed within the twelve month follow up period in both groups.

Conclusions:

Our data shows that the XtraLASIK treatment seems to be a equally efficient and safe procedure compared to conventional fs-LASIK. Regarding the visual acuity there was only a difference one week postoperative, in the later follow up both groups showed no difference regarding visual acuity and stability of the MRSE.

Financial Disclosure:

gains financially from product or procedure presented, research is funded, fully or partially, by a competing company, receives consulting fees, retainer, or contract payments from a competing company